4.4 Letter

Liver cirrhosis is independently associated with increased in-hospital mortality in patients undergoing left atrial appendage occlusion device implantation

Related references

Note: Only part of the references are listed.
Article Cardiac & Cardiovascular Systems

Utilization and procedural adverse outcomes associated with Watchman device implantation

Fouad Khalil et al.

Summary: The FDA approval of the Watchman device has led to its widespread use in the USA. A study was conducted to evaluate the nationwide utilization and adverse outcomes associated with Watchman device implantation in 2016, with findings showing a low overall complication rate of 1.9% and in-hospital mortality rate of 0.29%. The complication rates were lower than those reported in major randomized clinical trials (RCTs) and were similar to the European Watchman registry findings.

EUROPACE (2021)

Article Cardiac & Cardiovascular Systems

Outcomes of MitraClip Placement in Patients With Liver Cirrhosis

Khalid Sawalha et al.

Summary: Patients with liver cirrhosis who underwent MitraClip repair of MV were at higher risk of developing cardiogenic shock, without significant increase in in-hospital mortality, LOS or total cost. However, this study showed a trend toward higher rates of mortality, requirement of blood transfusion, mechanical ventilation, length of stay, and cost of care in cirrhosis patients.

CARDIOVASCULAR REVASCULARIZATION MEDICINE (2021)

Article Cardiac & Cardiovascular Systems

Outcomes and Effects of Hepatic Cirrhosis in Patients Who Underwent Transcatheter Aortic Valve Implantation

Ahmed S. Yassin et al.

AMERICAN JOURNAL OF CARDIOLOGY (2018)

Article Medicine, General & Internal

Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation A Randomized Clinical Trial

Vivek Y. Reddy et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)